Medical technology group
Siemens Healthineers wants to grow with Corona-antigen tests
The Logo and the lettering on the new headquarters of the medical technology group of Siemens Healthineers. Photo: Daniel Karmann/dpa
© dpa-infocom GmbH
The Corona pandemic has slowed down the business of the medical technology group of Siemens Healthineers. Among other things, with new Antigen Tests, the company intends to grow significantly.
The medical technology group of Siemens Healthineers want to achieve in the forthcoming financial year 2020/21 alone with Corona-antigen tests, with a turnover of at least 100 million euros.
The chief financial officer Jochen Schmitz announced on Monday at the presentation of the Figures for the past fiscal year 2019/2020. “This can be depending on the demand significantly,” said Schmitz. The UK Prime Minister and Boris Johnson had declared that his country intends to use the Quick-Tests that are supposed to deliver within 15 minutes extensive and reliable results, wide. From Slovakia and other countries, similar signals are coming from.
Siemens Healthineers has developed a Antigen rapid test for the Coronavirus and is going to bring it to the market. Previously, the Erlangen-based company PCR had Tests and antibody Tests on the market, and thus to a higher two-digit million amount to be implemented. The antibodies Tests were very hesitant demand, said Schmitz. He expects that will change after the introduction of a vaccine.
The sale of rapid tests to contribute to and lead the revenue back on a growth curve. After a downturn in the past fiscal year, revenue is expected to increase, on a comparable Basis by 5 to 8 percent. 2019/20 revenues were comparable to the almost stable remained at 14.5 billion euros, because of the generally difficult business atmosphere during the pandemic, especially on the American continent. The bottom line is that Siemens Healthineers 2019/20 had earned with 428 million euros less than in the previous year, as were 502 million euros in beech.
In this case, the Management to the group chief Bernd Monday that the environment for testing in Routine investigations improved, and the investment behavior in the U.S. starting in January 2021 and again attracts. Just Routine laboratory tests on other diseases as Corona had fallen in the past year.
Adjusted earnings per share Healthineers looks in the current fiscal year (end of September) in a range of 1.58 to 1.72 euros, according to comparable 1.61 euros in the previous year. In the forecast, the Acquisition of US cancer specialist Varian is not included. Healthineers want to complete the announced in the summer of 16.4 billion Dollar Acquisition is the largest transaction in the company’s history – in the first half of the year 2021. The group has mastered in September, a first capital increase of around EUR 2.7 billion. Another could follow in the coming year.
The fourth quarter showed, meanwhile, improvements compared to the previous quarter, as the diagnostics business is significantly lower volume of Testing for Routine investigations in connection with the Corona-pandemic suffered. Revenue and profit were due to the losses caused by Covid-19 year-on-year. However, chief Monday expressed satisfaction. In the medium-term objectives he holds.
In the final quarter of the fiscal year, sales decreased by 6.4 percent to 3.88 billion euros. Comparable to the Minus 2 percent. Currency effects and acquisitions and divestments are expected. The diagnostics business had recovered in comparison to the previous quarter, but with a comparable sales decrease of one percent is still slightly negative. The margins remained under pressure. Also the business of imaging, an improvement compared to the previous quarter, but also year-on-year.
Siemens Healthineers was gone in 2018 listed on the stock exchange, and was thus separate from the parent company, Siemens handy. However, Siemens still holds 79 percent of the Healthineers shares.
